Portfolio company Montara Therapeutics announced first development candidate for BrainOnly platform.
DEC 8, 2025
Montara Therapeutics is a preclinical-stage biopharmaceutical company pursuing novel approaches to develop safer and more efficacious treatments for neurological diseases
Montara Therapeutics is a preclinical-stage biopharmaceutical company pursuing novel approaches to develop safer and more efficacious treatments for neurological diseases. Montara’s BrainOnly platform allows brain-specific pharmacology utilizing existing and novel chemical warheads, restricting deleterious on-target off-tissue peripheral activity. BrainOnly holds the potential to drug numerous targets previously considered undruggable.